Forecast: Diabetes Medicine Sales in Australia

Diabetes medicine sales in Australia have shown significant fluctuations over the past decade. The period from 2013 to 2019 witnessed a decline, except for a few sporadic increases, notably in 2016 and 2017. However, from 2020 onwards, sales surged, with a marked increase in 2021 and subsequent years, reaching USD 36.2 per capita in 2023. The year-on-year growth over the last two years is an impressive 10.37% in 2023. The compound annual growth rate (CAGR) over the past five years stood at a robust 10.08%.

Future trends to watch for:

• Continued steady growth with a forecasted 5-year CAGR of 3.14% from 2024 onwards.
• Potential impact of new diabetes management technologies on medicine sales.
• Changes in healthcare policies and funding affecting accessibility and affordability of medications.
• Emerging competition from alternative treatments and generic drugs.